| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
NSC-45586 sodium targets PHLPP1 and PHLPP2 (Pleckstrin Homology Domain and Leucine-Rich Repeat Protein Phosphatase), which are protein phosphatases that dephosphorylate and inactivate AKT. The compound targets the PP2C phosphatase domain within these proteins. By inhibiting PHLPP, the compound activates AKT signaling in neuronal cells. This mechanism is distinct from other AKT activators such as SC79, providing a cleaner readout via AKT bias over ERK inhibition.
|
|---|---|
| ln Vitro |
In vitro, NSC-45586 sodium inhibits PHLPP1 and PHLPP2 activity, leading to activation of AKT in neurons. The compound shows selective inhibition of PHLPP isoforms. It preserves nucleus pulposus cell phenotype in intervertebral disc degeneration models. The compound's activity has been validated in various cellular systems. However, specific IC50 values for PHLPP inhibition are not extensively reported in the available literature.
|
| ln Vivo |
In vivo, NSC-45586 sodium has been studied for its potential in cancer treatment and neuroprotection. By activating AKT, the compound may promote neuronal survival and protect against neurodegeneration. It has been explored for its potential in intervertebral disc degeneration. In cancer models, PHLPP inhibition may affect tumor growth and survival. However, specific in vivo efficacy data and dosing regimens are not extensively detailed.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for NSC-45586 sodium typically involve phosphatase activity assays using purified recombinant PHLPP1 or PHLPP2 enzyme. The assay is performed in 96-well plates with assay buffer containing the enzyme and a phosphopeptide substrate (e.g., phospho-AKT peptide). The compound (typically 0.001-100 μM) is incubated with the enzyme and substrate at 37°C for 30-60 minutes. Phosphate release is detected using a malachite green or biomol green reagent. The IC50 is determined from dose-response curves.
|
| Cell Assay |
In vitro cellular assays for NSC-45586 sodium use neuronal cell lines or primary neurons. Cells are cultured in appropriate media and treated with various concentrations of the compound (typically 0.01-10 μM) for 1-24 hours. AKT phosphorylation (Ser473) is assessed by Western blotting. Cell survival and proliferation are assessed using MTT or CellTiter-Glo assays. In cancer cells, apoptosis and cell cycle effects are evaluated. The compound is typically dissolved in DMSO and diluted in culture media.
|
| Animal Protocol |
In vivo animal studies with NSC-45586 sodium would typically use mouse models of neurodegeneration, cancer, or intervertebral disc degeneration. The compound would be administered intraperitoneally or orally at doses of 1-30 mg/kg. In neurodegeneration models, neuronal survival and behavioral outcomes would be assessed. In cancer models, tumor growth would be monitored. However, specific protocols are not extensively detailed in the available literature.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of NSC-45586 sodium: The compound is soluble in DMSO at 82 mg/mL. It has a molecular weight of 413.4. Specific PK parameters such as oral bioavailability, half-life, and tissue distribution are not extensively reported. The compound is supplied as a sodium salt to enhance solubility. It is expected to have moderate lipophilicity and be metabolized by hepatic enzymes.
|
| Toxicity/Toxicokinetics |
The toxicity profile of NSC-45586 sodium is not extensively reported. As a PHLPP inhibitor that activates AKT, potential toxicities may include effects on cell survival and proliferation in normal tissues. The compound is for research use only and not for human therapeutic use. Standard toxicity studies would include acute toxicity in rodents and cytotoxicity assays in normal cell lines. No specific genotoxicity or cardiotoxicity data are reported.
|
| References | |
| Additional Infomation |
NSC-45586 sodium (CAS 6300-44-3) is a pan-inhibitor of PHLPP1 and PHLPP2 that activates AKT in neurons. It has a molecular formula of C20H17N6NaO3 and a molecular weight of 413.4. The compound is used in research on cancer, neurodegeneration, and intervertebral disc degeneration. It is available for research purposes only and is not approved for clinical use.
|
| Molecular Formula |
C20H18N6O3.NA+
|
|---|---|
| Molecular Weight |
413.38512
|
| Exact Mass |
413.134
|
| Elemental Analysis |
C, 58.25; H, 4.16; N, 20.38; Na, 5.57; O, 11.64
|
| CAS # |
6300-44-3
|
| Related CAS # |
NSC45586;739301-85-0
|
| PubChem CID |
135422008
|
| Appearance |
Brown to black solid powder
|
| Density |
1.43g/cm3
|
| Boiling Point |
675.7ºC at 760mmHg
|
| Flash Point |
362.5ºC
|
| Index of Refraction |
1.702
|
| LogP |
6.556
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
30
|
| Complexity |
607
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[Na+].OC(C1=C/C(=N/NC2C=CC(/N=N/C3C=C(C)C(N)=CC=3N)=CC=2)/C=CC1=O)=O
|
| InChi Key |
XPYXCDXPWJROPD-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H18N6O3.Na/c1-11-8-18(17(22)10-16(11)21)26-24-13-4-2-12(3-5-13)23-25-14-6-7-19(27)15(9-14)20(28)29;/h2-10,27H,21-22H2,1H3,(H,28,29);/q;+1
|
| Chemical Name |
sodium;5-[[4-[(2,4-diamino-5-methylphenyl)diazenyl]phenyl]diazenyl]-2-hydroxybenzoic acid
|
| Synonyms |
NSC-45586; NSC45586; NSC 45586
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~5 mg/mL (~12.12 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4190 mL | 12.0951 mL | 24.1902 mL | |
| 5 mM | 0.4838 mL | 2.4190 mL | 4.8380 mL | |
| 10 mM | 0.2419 mL | 1.2095 mL | 2.4190 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
